This week in transparency news: October 27 – November 2, 2018

by Staff writer,
Posted on 11/2/2018

Transparency in clinical trials is continually changing, and to stay on top of the news, TrialAssure brings a weekly round-up of some of the key stories surrounding disclosures in clinical trials. This week’s stories are as follows:

UK report finds that 50% of clinical trial results not published RAPS.org

A recent report by the UK House of Commons’ Science and Technology Committee is summarized in this article, with Member of Parliament and Committee Chair Norman Lamb saying that they “must act now to ensure current regulations are enforced and impose tough sanctions.” The report cites political reasons as a key factor of the fact that about half of clinical trial results in the UK are not published.

Read the full article here.

Call for more transparency in cancer clinical trials The BMJ

A new paper in The BMJ titled Reporting harms more transparently in trials of cancer drugs is calling for the reporting of clinical trials to use more accurate terms that do not downplay the seriousness of adverse reactions.

Read the full paper here.

What really happens with patient data? – Johnson & Johnson

In a blog article, Johnson & Johnson CMO Joanne Waldstreicher, M.D., opens up on how the company uses big data for its research, how patients benefit from real-world data collection, and why they share their own data for others to analyze.

Read the full blog post here.

Share: